College of Pharmaceutical Science, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, China; National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China.
Department of Diagnostic Ultrasound and Echocardiography, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
J Control Release. 2024 Oct;374:400-414. doi: 10.1016/j.jconrel.2024.08.024. Epub 2024 Aug 24.
Cellular iron is inseparably related with the proper functionalities of mitochondria for its potential to readily donate and accept electrons. Though promising, the available endeavors of iron chelation antitumor therapies have tended to be adjuvant therapies. Herein, we conceptualized and fabricated an "iron-phagy" nanoparticle (Dp44mT@HTH) capable of inducing the absolute devastation of mitochondria via inhibiting the autophagy-removal of impaired ones for promoting cancer cell death. The Dp44mT@HTH with hyaluronic acid (HA) as hydrophilic shell can specifically target the highly expressed CD44 receptors on the surface of 4T1 tumor cells. After internalization and lysosomal escape, the nanoparticle disassembles in response to the reactive oxygen species (ROS), subsequently releasing the iron chelator Dp44mT and autophagy-inhibitory drug hydroxychloroquine (HCQ). Dp44mT can then seize cellular Fe to trigger mitochondrial dysfunction via respiratory chain disturbance, while HCQ not only lessens Fe intake, but also impedes fusions of autophagosomes and lysosomes. Consequentially, Dp44mT@HTH induces irreversible mitochondrial impairments, in this respect creating a substantial toxic stack state that induces apoptosis and cell death. Initiating from the perspective of endogenous substances, this strategy illuminates the promise of iron depletion therapy via irreversible mitochondrial damage induction for anticancer treatment.
细胞内铁与线粒体的正常功能密切相关,因为它具有易于供电子和受电子的特性。尽管很有前途,但现有的铁螯合抗肿瘤治疗方法往往是辅助治疗。在此,我们设计并制备了一种“铁自噬”纳米颗粒(Dp44mT@HTH),它能够通过抑制受损线粒体的自噬清除来诱导线粒体的彻底破坏,从而促进癌细胞死亡。具有透明质酸(HA)作为亲水壳的 Dp44mT@HTH 可以特异性靶向 4T1 肿瘤细胞表面高表达的 CD44 受体。在内化和溶酶体逃逸后,纳米颗粒会响应活性氧(ROS)而解体,随后释放铁螯合剂 Dp44mT 和自噬抑制剂羟氯喹(HCQ)。Dp44mT 随后可以夺取细胞内的 Fe 来通过呼吸链干扰引发线粒体功能障碍,而 HCQ 不仅减少了 Fe 的摄取,还阻碍了自噬体和溶酶体的融合。因此,Dp44mT@HTH 诱导不可逆的线粒体损伤,从而在这方面造成了诱导细胞凋亡和死亡的大量毒性堆积状态。从内源性物质的角度出发,这种策略为通过不可逆的线粒体损伤诱导来进行癌症治疗的铁耗竭疗法提供了前景。